{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T23:47:43Z","timestamp":1780444063678,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.berh.2022.101755","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T08:17:06Z","timestamp":1654157826000},"page":"101755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Impaired bone health as a co-morbidity of epilepsy"],"prefix":"10.1016","volume":"36","author":[{"given":"No\u00e9mi Becser","family":"Andersen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas Rye","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2022.101755_bib1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/seiz.2002.0593","article-title":"Refractory epilepsy: a progressive, intractable but preventable condition?","volume":"11","author":"Kwan","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.berh.2022.101755_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MED.0000000000000366","article-title":"Epilepsy and osteoporosis risk","volume":"24","author":"Dussault","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.berh.2022.101755_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.0b013e31825f0466","article-title":"Falls and fractures in patients chronically treated with antiepileptic drugs","volume":"79","author":"Shiek Ahmad","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2022.101755_bib4","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.spen.2007.08.006","article-title":"Bone consequences of epilepsy and antiepileptic medications","volume":"14","author":"Samaniego","year":"2007","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.berh.2022.101755_bib5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/ane.12118","article-title":"Antiepileptic drugs and high prevalence of low bone mineral density in a group of inpatients with chronic epilepsy","volume":"128","author":"Beerhorst","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.berh.2022.101755_bib6","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0404.1999.tb00675.x","article-title":"Fracture risk is increased in epilepsy","volume":"99","author":"Vestergaard","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.berh.2022.101755_bib7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1600-0404.2005.00474.x","article-title":"Epilepsy, osteoporosis and fracture risk - a meta-analysis","volume":"112","author":"Vestergaard","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.berh.2022.101755_bib8","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/art.40137","article-title":"American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2022.101755_bib9","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.yebeh.2004.02.007","article-title":"Prevalence of epilepsy and health status of adults with epilepsy in Georgia and Tennessee: behavioral risk factor surveillance system","volume":"5","author":"Kobau","year":"2004","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.berh.2022.101755_bib10","doi-asserted-by":"crossref","first-page":"106511","DOI":"10.1016\/j.yebeh.2019.106511","article-title":"An explorative literature review of the multifactorial causes of osteoporosis in epilepsy","volume":"100","author":"Diemar","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.berh.2022.101755_bib11","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00198-019-05000-y","article-title":"Longitudinal assessment of health-related quality of life in osteoporosis: data from the population-based Canadian Multicentre Osteoporosis Study","volume":"30","author":"Hopman","year":"2019","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.berh.2022.101755_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0020-1383(95)00189-1","article-title":"Incidence of five common fracture types in an institutional epileptic population","volume":"27","author":"Desai","year":"1996","journal-title":"Injury"},{"key":"10.1016\/j.berh.2022.101755_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archneurol.2010.341","article-title":"Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis","volume":"68","author":"Jette","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.berh.2022.101755_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1080\/14740338.2019.1625887","article-title":"An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs","volume":"18","author":"Miziak","year":"2019","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.berh.2022.101755_bib15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.seizure.2015.02.022","article-title":"Interactions between antiepileptic drugs and hormones","volume":"28","author":"Svalheim","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.berh.2022.101755_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0028-3886.63796","article-title":"Early predisposition to osteomalacia in Indian adults on phenytoin or valproate monotherapy and effective prophylaxis by simultaneous supplementation with calcium and 25-hydroxy vitamin D at recommended daily allowance dosage: a prospective study","volume":"58","author":"Krishnamoorthy","year":"2010","journal-title":"Neurol India"},{"key":"10.1016\/j.berh.2022.101755_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/bmj.4.5727.69","article-title":"Osteomalacia with long-term anticonvulsant therapy in epilepsy","volume":"4","author":"Dent","year":"1970","journal-title":"Br Med J"},{"key":"10.1016\/j.berh.2022.101755_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/BF02441155","article-title":"Anticonvulsant drug-induced osteomalacia: alterations in mineral metabolism and response to vitamin D3 administration","volume":"27","author":"Hahn","year":"1979","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.berh.2022.101755_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-0404.1983.tb04809.x","article-title":"Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?","volume":"68","author":"Tjellesen","year":"1983","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.berh.2022.101755_bib20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.4314\/eamj.v87i4.62411","article-title":"Bone metabolism in healthy ambulatory control premenopausal women and in epileptics on anti-convulsant drugs","volume":"87","author":"Kwasa","year":"2010","journal-title":"East Afr Med J"},{"key":"10.1016\/j.berh.2022.101755_bib21","first-page":"550","article-title":"Bone density of ambulatory adult patients receiving long-term anticonvulsant drug therapy","volume":"12","author":"Ashjazadeh","year":"2009","journal-title":"Arch Iran Med"},{"key":"10.1016\/j.berh.2022.101755_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/2249-4863.192338","article-title":"Impact of antiepileptic drugs on bone health: need for monitoring, treatment, and prevention strategies","volume":"5","author":"Arora","year":"2016","journal-title":"J\u00a0Fam Med Prim Care"},{"key":"10.1016\/j.berh.2022.101755_bib23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pediatrneurol.2004.03.021","article-title":"Effect of carbamazepine and valproate on bone mineral density","volume":"31","author":"Ecevit","year":"2004","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.berh.2022.101755_bib24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00223-016-0109-7","article-title":"Monotherapy with levetiracetam versus older AEDs: a randomized comparative trial of effects on bone health","volume":"98","author":"Hakami","year":"2016","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.berh.2022.101755_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1535-7597.2003.03306.x","article-title":"The association between antiepileptic drugs and bone disease","volume":"3","author":"Pack","year":"2003","journal-title":"Epilepsy Current"},{"key":"10.1016\/j.berh.2022.101755_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.phrs.2003.11.011","article-title":"The effect of valproate on bone mineral density in adult epileptic patients","volume":"50","author":"Boluk","year":"2004","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.berh.2022.101755_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2009.12.015","article-title":"Effect of long-term valproate monotherapy on bone mineral density in adults with epilepsy","volume":"290","author":"Triantafyllou","year":"2010","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.berh.2022.101755_bib28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0022-3476(95)70304-7","article-title":"Effect of carbamazepine and valproate on bone mineral density","volume":"127","author":"Sheth","year":"1995","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.berh.2022.101755_bib29","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.57.3.445","article-title":"Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy","volume":"57","author":"Sato","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.berh.2022.101755_bib30","series-title":"Diagnosis and management","author":"Epilepsies","year":"2012"},{"key":"10.1016\/j.berh.2022.101755_bib31","series-title":"Epilepsy and bone health","author":"Andersen","year":"2022"},{"key":"10.1016\/j.berh.2022.101755_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.seizure.2021.01.008","article-title":"Metabolic bone disease in patients with epilepsy and the use of antiepileptic drugs - insight from a Danish cross-sectional study","volume":"86","author":"Baddoo","year":"2021","journal-title":"Seizure"},{"key":"10.1016\/j.berh.2022.101755_bib33","series-title":"WHO scientific group on the assessment of osteoporosis at primary health Care level. Summary meeting report brussels, Belgium, 5-7 may 2004","author":"Bonjour","year":"2004"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694222000146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:42Z","timestamp":1761499422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694222000146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1521694222000146"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2022.101755","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired bone health as a co-morbidity of epilepsy","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2022.101755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101755"}}